Speaker(s): 

Nikita Garg, MD- Internal Medicine Resident PGY-3, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Connor Dougherty, DO, Staff Member, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the epidemiology and pathogenesis of CDI, including its rising incidence in both hospitalized and community settings. Identify key risk factors for primary and recurrent CDI, including antibiotic exposure, advanced age, and immunologic vulnerability.
• Differentiate the clinical presentations of nonsevere, severe, and fulminant CDI, and recognize signs of complications such as toxic megacolon. Outline the diagnostic approach, including appropriate use of laboratory testing and imaging modalities.
• Review current treatment guidelines for initial, recurrent, and fulminant CDI, including the role of fidaxomicin, vancomycin, metronidazole, and fecal microbiota transplantation (FMT).
• Discuss infection control measures critical to preventing transmission, including hand hygiene and contact precautions.
• Recognize the limitations of repeat testing and understand when reassessment is clinically indicated.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Connor Dougherty, DO, Karlyn Paglia, MD, Juan R. Escobar, MD, Melad Kamel, MD, Shashank Kotakonda, MD, Jayalakshmi Nair, MD, Jignesh Patel, MD, Jameson Woodard, MD, Hasan Zerti, MD, Robert Yanoshak, DO, and Habib Hamoud, MD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.